NDASUBCUTANEOUSSOLUTION
Approved
Jul 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LYMPHAZURIN (isosulfan blue) by Medtronic is 12. First approved in 1981.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYMPHAZURIN (isosulfan blue) is a subcutaneous diagnostic dye that binds to serum proteins and is taken up by lymphatic vessels to delineate lymph node anatomy during surgical procedures. It is used as an intraoperative imaging aid to identify sentinel lymph nodes in cancer surgery and other lymphatic mapping applications. The drug works by visual staining of lymphatic vessels, enabling surgeons to locate and remove lymph nodes for pathological examination.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a contracting commercial team and shift toward operational efficiency roles.
Mechanism of Action
12.2 Pharmacodynamics Following subcutaneous administration, isosulfan blue injection 1% binds to serum proteins and is picked up by the lymphatic vessels. Thus, the lymphatic vessels are delineated by the blue dye. 12.3 Pharmacokinetics Up to 10% of the subcutaneously administered dose of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With 1,030 linked jobs, LYMPHAZURIN presents broad career opportunity within Medtronic, though the portfolio tilt toward operational and finance roles reflects LOE positioning. Commercial roles remain available but growth is limited; manufacturing and operational excellence are expanding areas as the product matures.
Sales Representative
Worked on LYMPHAZURIN at Medtronic? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.